These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10370776)

  • 1. Rationing in cancer treatment: is the identification of essential cytotoxic drugs feasible?
    Sessa C
    Ann Oncol; 1999 Apr; 10(4):373-4. PubMed ID: 10370776
    [No Abstract]   [Full Text] [Related]  

  • 2. [Economic effects of "molecular" medicine].
    Riemann JF
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
    [No Abstract]   [Full Text] [Related]  

  • 3. [Innovative therapy, early and cost-benefit assessment].
    Dierks C
    Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
    [No Abstract]   [Full Text] [Related]  

  • 4. Does evidence-based medicine really reduce costs?
    Kolodziej MA
    Oncology (Williston Park); 2011 Mar; 25(3):214, 218. PubMed ID: 21548463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
    Mayor S
    BMJ; 2016 Feb; 352():i1208. PubMed ID: 26926879
    [No Abstract]   [Full Text] [Related]  

  • 6. Can treatment costs be tamed?
    Malakoff D
    Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
    [No Abstract]   [Full Text] [Related]  

  • 7. Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care.
    Malin JL
    J Clin Oncol; 2020 Feb; 38(4):367-371. PubMed ID: 31804871
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cost/benefit analysis of cancer drugs].
    Jordan B
    Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
    Tannock IF; Ratain MJ; Goldstein DA; Lichter AS; Rosner GL; Saltz LB
    J Clin Oncol; 2021 Mar; 39(9):950-955. PubMed ID: 33555940
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.
    Smith TJ; Hillner BE; Desch CE
    J Natl Cancer Inst; 1993 Sep; 85(18):1460-74. PubMed ID: 8360929
    [No Abstract]   [Full Text] [Related]  

  • 11. Optional copayments on anti-cancer drugs.
    van de Vooren K; Curto A; Garattini L
    BMJ; 2013 Jan; 346():f349. PubMed ID: 23347986
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why clinical oncologists should talk about the price of cancer drugs.
    Berlinger N
    Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
    [No Abstract]   [Full Text] [Related]  

  • 14. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer Drugs Fund of minimal benefit.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
    [No Abstract]   [Full Text] [Related]  

  • 16. Trends in the Cost of Cancer Care: Beyond Drugs.
    Laviana AA; Luckenbaugh AN; Resnick MJ
    J Clin Oncol; 2020 Feb; 38(4):316-322. PubMed ID: 31804864
    [No Abstract]   [Full Text] [Related]  

  • 17. Putting a price on hope.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(17):1274-5. PubMed ID: 22914787
    [No Abstract]   [Full Text] [Related]  

  • 18. Detoxifying the concept of rationing.
    Sabin J
    J Clin Ethics; 2014; 25(2):116-9. PubMed ID: 24972061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Researching the cost of research.
    Wright JR; Levine MN
    J Clin Oncol; 2003 Nov; 21(22):4081-2. PubMed ID: 14559890
    [No Abstract]   [Full Text] [Related]  

  • 20. WHO Essential Medicines Committee spotlights unaffordable drugs.
    Furlow B
    Lancet Oncol; 2021 Nov; 22(11):1503. PubMed ID: 34627500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.